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Abstract
Background: Progressive encephalopathy (PE) in children is a heterogeneous group of diseases
mainly composed of metabolic diseases, but it consists also of neurodegenerative disorders where
neither metabolic nor other causes are found. We wanted to estimate the incidence rate and
aetiology of PE, as well as the age of onset of the disease.
Methods: We included PE cases born between 1985 and 2003, living in Oslo, and registered the
number presenting annually between 1985 and 2004. Person-years at risk between 0 and 15 years
were based on the number of live births during the observation period which was divided into four
5-year intervals. We calculated incidence rates according to age at onset which was classified as
neonatal (0–4 weeks), infantile (1–12 months), late infantile (1–5 years), and juvenile (6–12 years).
Results: We found 84 PE cases representing 28 diagnoses among 1,305,997 person years, giving
an incidence rate of 6.43 per 100,000 person years. The age-specific incidence rates per 100,000
were: 79.89 (<1 year), 8.64 (1–2 years), 1.90 (2–5 years), and 0.65 (>5 years). 66% (55/84) of the
cases were metabolic, 32% (27/54) were neurodegenerative, and 2% (2/84) had HIV
encephalopathy. 71% (60/84) of the cases presented at < 1 year, 24% (20/84) were late infantile
presentations, and 5% (4/84) were juvenile presentations. Neonatal onset was more common in
the metabolic (46%) (25/55) compared to the neurodegenerative group (7%) (2/27). 20% (17/84)
of all cases were classified as unspecified neurodegenerative disease.
Conclusion: The overall incidence rate of PE was 6.43 per 100,000 person years. There was a
strong reduction in incidence rates with increasing age. Two-thirds of the cases were metabolic, of
which almost half presented in the neonatal period.
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Background
Progressive neurological disease in children poses an
important challenge to our health system in terms of diag-
nosis and management [1-3]. In the present study, we
focused on children presenting with signs of progressive
CNS disease associated with impairment of cognitive
functioning, designated progressive encephalopathy (PE).
In the literature, PE is often used interchangeably with
neurodegenerative encephalopathy. Both terms lack a
firm definition, but we preferred PE because it encom-
passes clinically progressive conditions without demon-
strable neuronal loss as well as those with a demonstrable
loss of neural tissue, most often detected by magnetic res-
onance imaging (MRI) examination.
Although the different diseases causing PE are individu-
ally rare, their cumulative incidence has been estimated to
be 0.5 per 1000 live births [4], which is within the same
range as other major neurological impairments, such as
neural tube defects [5] or infantile hydrocephalus [6], and
approximately half the incidence of cerebral palsy in full
term children [7]. PE is predominantly caused by inborn
errors of metabolism, hereafter called metabolic diseases.
PE also contains a relatively large mixed group of neuro-
degenerative disorders without an identifiable metabolic
deficiency, hereafter designated neurodegenerative dis-
ease. Infectious, inflammatory or toxic aetiologies may
also be considered as causes of PE. Epidemiological stud-
ies have most often focused on the cumulative incidence
of known diagnoses associated with PE, particularly met-
abolic diseases. Cases with such diagnoses have either
been discovered through screening programs for meta-
bolic diseases or they have been registered after clinical
presentation suggestive of metabolic deficiency [8-10].
The burden of disease may be heavily felt by patients and
caregivers when the diagnosis remains unknown despite
extensive investigation. It has been estimated that approx-
imately one-third of all paediatric brain disorders without
a known diagnosis, also called "anonymous" brain disor-
ders, can be classified as PE [11]. As epidemiological data
are scarce, we aimed to estimate the overall incidence rate
of PE with its different aetiologies and to determine the
age of onset of symptoms of the disease.
Methods
Case definition
In accordance with Uvebrant et al [12], PE was divided
into metabolic, neurodegenerative, and infectious aetiol-
ogy groups. The metabolic group was divided into disor-
ders involved in metabolic processes related to subcellular
organelles (lysosomes, mitochondrial respiratory chain,
and peroxisomes) or defects of intermediate metabolism
(organic acidurias, fatty acids oxidation disorders, urea
cycle disorders, galactosemia, and unspecified intermedi-
ate metabolic defects). The latter group contained a few
patients in whom specific management, such as a galac-
tose free diet in galactosemia, protein restriction, and vita-
min B12 supplementation in methylmalonic aciduria,
and appropriate caloric supply in fatty acid oxidation
defects, prevented them from developing clinical signs of
disease progression.
The neurodegenerative group consisted of patients with
progressive loss of neural tissue, where a metabolic or
other aetiology could not be detected. This group was sub-
divided into a group of patients with a specified or known
diagnosis and a group of patients in whom an aetiological
diagnosis had not been identified despite extensive work
up. The degenerative course of the disease in the unspeci-
fied degenerative group was documented with repeated
clinical assessments and MRI examination of the brain
showing atrophy of brain tissue. We classified patients
according to the part of the CNS that was predominantly
affected by the degenerative process: cerebral cortex, cere-
bral white matter, basal ganglia, cerebellum, and brain
stem. The infectious group consisted of patients with
encephalopathy caused by infectious agents, for example
human immunodeficiency virus (HIV). We recorded the
age of onset of symptoms of the disorder and the age
when an aetiological diagnosis was established. In the
patients with unspecified neurodegenerative disease, we
assigned the time of "diagnosis" as the age when a down-
hill course in each case was recognized. The age of onset
was defined as neonatal (0–4 weeks), infantile (1–12
months), late infantile (1–5 years), juvenile (6–12 years),
or late juvenile (>12 years).
We excluded patients with spinocerebellar ataxia and spi-
nal muscular atrophy and other neuromuscular disorders
if not accompanied by signs of encephalopathy. We did
not include children with multiple sclerosis, as they usu-
ally do not exhibit disturbances of cognitive functioning
in the early years. Developmental disorders such as Rett
syndrome and autism were excluded. In Rett syndrome,
there is a period of regression in the early phase. However,
mental capacity does not continue to deteriorate in this
disorder [13]. In autism, there may be a limited period of
regression. However, autism spectrum disorders are not
typically associated with progressive brain atrophy
detected by MRI. The two diseases detected by the Norwe-
gian newborn screening program, phenylketonuria and
congenital hypothyroidism, were also excluded from the
study, as affected individuals would not present with signs
of encephalopathy.
Search procedure
Before 1998, the population of Oslo was serviced by the
paediatric departments at Aker and Ullevål University
hospitals. Since their merger in 1998, Ullevål University
Hospital has been the only paediatric ward servicing chil-BMC Pediatrics 2007, 7:25 http://www.biomedcentral.com/1471-2431/7/25
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dren between 0 and 15 years in Oslo. All medical diag-
noses in children hospitalized at the two hospitals since
1985 have been stored in a common electronic registry of
diagnoses (ERD). Because the national diagnostic labora-
tory for metabolic diseases is located at Rikshospitalet-
Radiumhospitalet Medical Center (RRMC) in Oslo, we
supplemented our ascertainment with the RRMC diagnos-
tic data. All diagnoses in the ERD had been coded accord-
ing to the International Classification of Diseases (ICD).
When we conducted our search in the ERD, we retrieved
the ICD code and birth year for each patient. We only con-
sidered children born between 1985 and 2003 living in
Oslo during this period. The ERD was searched for codes
in ICD-8 (before 1986) [14], ICD-9 (between 1986 and
1998) [15], and ICD-10 (after 1998) [16] compatible with
PE (Table 1). The search resulted in a list of potential cases
for the study. Subsequently, the medical charts and
reports of the MRI examinations were critically reviewed
(PS, OJK) to solely include patients who complied with
our case definition criteria. We also consulted the Depart-
ment of Pathology at Ullevål University Hospital to
retrieve cases diagnosed at the post mortem examination
with variant Creutzfelt-Jacobs disease (vCJD) or subacute
sclerosing panencephalitis (SSPE).
Incidence rates and cumulative incidences
As the admittance age to the paediatric departments had
been limited to 15 years, we defined the age of the "at-
risk" population for developing PE to be between 0 and
15 years of age. With a historical cohort design, only sub-
jects born between 1985 and 2003 residing in Oslo were
included. We registered new cases of PE having presented
annually between 1985 and 2004, a 20-year observation
period. In order to evaluate time trends, we divided the
observation period into four periods: 1985–89, 1990–94,
1995–99, and 2000–04. Although the youngest patients
were born in 2003, we chose to include 2004 as the last
year of the observation period accepting the fact that
ascertainment for this year could be an underestimate
Incidence rates of PE were calculated as the number of
cases divided by the number of person years at risk,
expressed per 100,000 person years. The calculations of
person years were based on the number of live births dur-
ing the observation period. Person years for 1985 were
estimated as half the number of live births for this year
(5,539 × 0.5 = 2,770), person years for 1986 as half the
number of live births for this year (5,959 × 0.5) + the
number of live births for 1985 (5,539) = 8,519, person
years for 1987 as half the number of live births for this
year (6,243 × 0.5) + live births for 1985 + 1986 (5,539 +
5,959) = 14,620, and so forth (Figure 1). These numbers
are approximations for the at-risk population, as migra-
tion of individuals in and out of Oslo was not accounted
for.
In order to compare our results with other investigations,
we also calculated cumulative incidences per 1000 live
births. This was the number of cases divided by the total
number of live births in Oslo during 1985 to 2003. The
surveillance period for case registration in this study was
between 1.1.2004 and 1.8.2006.
Table 1: ICD codes used in the search for cases of progressive encephalopathy in children born between 1985 and 2003
Diseases ICD-10 (>1998) ICD-9 (1986–1998) ICD-8 (<1986)
Inborn errors of metabolism
Amino acidopathies E70–E72 270 270
Carbohydrate metabolism E74 271 271
Sphingolipids and other lipid storage disorders E75 272 272
Glucoseaminoglycans (mucopolysaccharidoses) E76 277.5 273
Glycoprotein metabolism E77 277.5–277.9 270–273
Purin and pyrimidine E79 277.2 270
Mineral metabolism E83 275 273
Other aetiological diagnoses
Systemic atrophies primarily affecting CNS G10–G13 333 331
Extrapyramidal and other movement disorders G20–G26 333 332
Other CNS degenerative diseases G30–G32 340 340–341
Demyelinating disorders G35–G37 340–341 340–341
HIV with dementia B22 - -
Unspecified/Descriptive diagnoses
Unspecified metabolic disease E88.9 NA NA
Encephalopathy G93.4; G93.9 348.3; 348.9 781.7
Other CNS disease G96 348.3 NA
NA: Not availableBMC Pediatrics 2007, 7:25 http://www.biomedcentral.com/1471-2431/7/25
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Statistics
The Epi Info 6 statistical software was used for data entry
and analysis of frequency distribution of variables. Popu-
lation statistics for Oslo were provided by the Medical
Birth Registry of Norway. The relative risk of PE according
to time period and age at onset of disease was estimated
with Poisson regression using STATA 9.0. Confidence
intervals (CI) for incidence rates were calculated accord-
ing to Greenland & Rothman [17], while CI for propor-
tions were based on the Poisson distribution [18]. Odds
ratios (OR) were calculated using contingency tables, and
p-values were calculated using Fisher's exact test. Differ-
ences between median values of age were calculated using
the Mann-Whitney U test.
Ethics
The Norwegian Social and Health Directorate and the
Regional Ethics Committee approved the study.
Results
We found 84 PE cases among 1,305,997 person years, giv-
ing an overall incidence rate of 6.43 per 100,000 person
years (95% CI 5.15–7.97). The mean incidence rate
between 1999 and 2002, the most representative part of
the observation period, was 6.13 per 100,000 person years
(95% CI 4.17–9.0) (Figure 2). There was no significant
time trend in incidence, but there was a strong and signif-
icant reduction in the risk of PE with increasing age of the
child (Table 2). Likewise, when the incidence rates for
metabolic and neurodegenerative cases were assessed sep-
arately, there were no significant time trend changes (data
not shown). The age-specific incidence rates per 100,000
were: 79.89 (<1 year), 8.64 (1–2 years), 1.90 (2–5 years),
and 0.65 (>5 years) (95% CI not shown). In a population
with equal number of children in each birth cohort (age
standardization), this would correspond to an average
incidence rate of about 6.4 new cases per 100,000 person
years for the childhood population 0 to 15 years of age.
The proportions of the various aetiological categories and
their overall incidence rates calculated for the whole
observation period are shown in Table 3. There were 56
boys (66.7%) (95% CI 55.5–76.6) and 28 girls (33.3%)
(95% CI 23.4–44.5).
The overall cumulative incidence of PE among 138,550
live births was 0.60 per 1000 (95% CI 0.47–0.73). Other
cumulative incidences were: metabolic diseases 0.40
(95% CI 0.30–0.50), lysosomal storage disorders 0.17
(95% CI 0.10–0.24), and organic acidurias combined
with fatty acid oxidation defects 0.12 (95% CI 0.06–0.18),
per 1000 live births.
The age of onset of disease was distributed as neonatal in
32.1% (27/84), infantile in 39.3% (33/84), early juvenile
in 23.8% (20/84), and juvenile in 4.8% (4/84) (Table 4).
None of the cases had late juvenile onset. 71.4% (60/84)
of the cases presented during the first year of life. In the
metabolic group 45.5% (25/55) had neonatal onset, com-
pared to 7.4% (2/27) in the neurodegenerative group (p <
0.001). The median age at the time of diagnosis in the
neurodegenerative group was 4.5 years (25th – 75th quar-
tiles 1.8 to 10.0 years), compared to 0.5 years (25th – 75th
quartiles 0.02 to 3.0 years) in the metabolic group (p <
0.001).
The 28 different diagnoses assigned to the individual cases
(Table 5) included patients with rare and novel diseases,
such as congenital neuronal ceroid lipofuscinosis caused
by mutations in the Cathepsin D gene [19], 2-methylbu-
tyrylglycinuria [20] confirmed by mutation analysis
Table 2: Relative risks of progressive encephalopathy according 
to time period and age estimated as incidence rate ratios with 
95% confidence intervals using Poisson regression
Incidence rate ratios
Time periode
1985–89 1.0 (reference value)
1990–94 0.84 (0.41–1.73)
1995–99 1.39 (0.73–2.65)
2000–04 1.11 (0.57–2.16)
Age (y)
<1 1.0 (reference value)
1–1.99 0.11 (0.06–0.20)
2–5 0.02 (0.01–0.05)
>5 0.01 (0.00 – 0.02)
Person years during the observation period Figure 1
Person years during the observation period. The 
number of person years for each year increased gradually 
until 1999 when the at-risk population included the complete 
age cohort between 0 and 15 years.BMC Pediatrics 2007, 7:25 http://www.biomedcentral.com/1471-2431/7/25
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(Andresen B, personal communication), and Cockayne
syndrome caused by a novel mutation in the CSA gene
[21]. The neurodegenerative group included three
patients with congenital microphthalmia and brain atro-
phy [22] and one patient with a phenotype compatible
with pontocerebellar hypoplasia/atrophy and spinal mus-
cular atrophy [23]. Two patients with fatal HIV encepha-
lopathy were included, while cases with vCJD, SSPE, and
juvenile Huntington disease were not found. Patients with
glycosylation defects were not identified during the obser-
vation period. However, two siblings had presented with
this type of disorder in 1984 [24].
Discussion
Our investigation showed that 6.0 to 6.5 per 100,000 chil-
dren between 0 and 15 years of age presented with signs
of PE annually. From 1999 on the population was com-
plete and included all person years between 0 and 15
years at risk for getting PE. However, the incidence rates
from 2003 and 2004 may be underestimated, as the
observation time for children born in 2003 was short.
Thus, the most representative part of the observation
period was between 1999 and 2002 with an average inci-
dence rate of 6.13 per 100,000 person years (see Figure 2).
There was a strong tendency for PE to present early in life,
as 32.1% of the cases presented before 4 weeks and 39.3%
presented between 1 and 12 months of age (see Table 4).
This corresponded to an incidence rate of almost 80 per
100,000 person years below 1 year, approximately 13
times more common than the mean incidence rate in the
total childhood population. The male to female ratio of 2
could not be explained by known X-linked inherited dis-
orders, which occurred in only four boys in our study.
However, males outnumber females with regards to sev-
eral types of neurological handicaps, such as mental retar-
dation [25] and autism [26].
Incidence rates expressed per person years have not been
used as a measure of frequency of PE by other investiga-
tors. Consequently, the frequency of known diagnoses in
our study was not directly comparable with similarly
designed epidemiological studies. However, the cumula-
Incidence rates of progressive encephalopathy Figure 2
Incidence rates of progressive encephalopathy. The inci-
dence rates during the last 10 years of the observation period are 
shown. Before 1994, the incidence rates were overestimated due 
to artificially low numbers of person years. The incidence rates for 
2003 and 2004 may be underestimated due to short observation 
time. However, a time trend analysis using incidence rate ratios 
did not demonstrate any trend changes (data shown in Table 2). 
During the most representative period, 1999 to 2002, the mean 
incidence rate was 6.13 per 100,000 person years (horizontal 
line).
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Table 3: Aetiological classification and incidence rates in children with progressive encephalopathy
n % 95% CI IR per 100,000 person yearsa 95% CI
I. Metabolic 55 65.5 54.3–75.5 4.21 3.23–5.49
A. Subcellular organelles 28 33.3 23.4–44.5 2.14 1.48–3.11
Lysosomal 23 27.4 18.2–38.2 1.76 1.17–2.65
Mitochondrial 3 3.6 0.7–10.1 0.23 0.07–0.71
Peroxisomal 2 2.4 0.3–8.3 0.15 0.04–0.61
B. Intermediate metabolism 27 32.1 22.4–43.2 2.07 1.42–3.02
Organic aciduria 11 13.1 6.7–22.2 0.84 0.47–1.52
Fatty acid oxidation defect 6 7.1 2.7–14.9 0.46 0.21–1.02
Urea cycle disorders 4 4.8 1.3–11.7 0.31 0.12–0.82
Galactosemia 4 4.8 1.3–11.7 0.31 0.12–0.82
Unspecified 2 2.4 0.3–8.3 0.15 0.04–0.61
II. Neurodegenerative 27 32.1 22.4–43.2 2.10 1.42–3.02
A. Specified 10 11.9 5.9–20.8 0.77 0.41–1.42
B. Unspecified 17 20.2 12.3–30.4 1.30 0.81–2.09
III. Infectious 2 2.4 0.3–8.3 0.15 0.04–0.61
Total 84 100 - 6.43 5.19–7.97
CI: confidence interval; IR: incidence rates
aNot adjusted for time periodsBMC Pediatrics 2007, 7:25 http://www.biomedcentral.com/1471-2431/7/25
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tive incidence of 0.60 per 1000 live births was close to that
of 0.58 per 1000 live births in West Sweden [12]. For met-
abolic diseases, the cumulative incidence of 0.40 per 1000
(95% CI 0.30–0.50) was somewhat higher than 0.27 per
1000 live births (95% CI 0.269–0.271) in a large-scale
Italian study comprising 200 diseases [27]. We did not
include phenylketonuria, which has a cumulative inci-
dence of 7.5 per 100,000 live births in Norway [28]. The
cumulative incidence of mitochondrial encephalopathy
in our study was as low as 2.2 per 100,000 live births,
approximately one-third of the cumulative incidence
found in Sweden [29]. With a historic cohort design, we
were dependent on the information given in the medical
charts and may therefore have missed some accuracy
regarding diagnoses, particularly for the early years of the
observation period. Mitochondrial disorders may have
been inadequately diagnosed in Norway. The cumulative
incidence of lysosomal storage diseases of 0.17 per 1000
(95% CI 0.10–0.24) in our study was comparable to 0.13
per 1000 in Western Australia [30] and 0.25 per 1000 in
Portugal [10], while the combination of organic acidurias
and fatty acid oxidation defects of 0.12 per 1000 (95% CI
0.06–0.18) in our study was similar to that of 0.13 per
1000 live births in Germany [31]. There was a trend
towards identifying an exact molecular cause in patients
with known diseases. The potentially increased incidence
rate of PE in the non-western immigration population,
associated with higher proportion of consanguineous
marriages, will be addressed in a separate study.
The neurodegenerative group comprised 32.1% (95% CI
22.4–43.2%) (see Table 3) of all cases, which is compara-
ble to the proportion (28%) in West Sweden [12]. How-
ever, we did not include Rett syndrome in our study. The
proportion of cases with unspecified neurodegenerative
diagnosis of 20.2% (95% CI 12.3–30.4) occurred at an
incidence rate of 1.3 per 100,000 person years. The inci-
dence rate of this heterogeneous group has not previously
been reported in the literature. Despite extensive investi-
gation, this group may contain patients with rare meta-
Table 5: Diagnoses in 84 children with progressive encephalopathy
Diagnoses (n)
Lysosomal I cell disease (1), alpha-Mannosidosis (1), MLD (3), MPS1 (4), MPS2 (1), MPS3 (1), NCL congenital [19] (3), NCL3 
(4), NPC (3), Salla disease (1), Sandhoff disease (1)
Mitochondrial Leigh disease (3)
Peroxisomal Adrenoleukodystrophy X-linked (2)
Organic aciduria 2-methylbutyryl CoA dehydrogenase deficiency [20]a (1), glutaric aciduria (1), L2 hydroxy glutaric aciduria (2), 
methyl malonic aciduriab (2), multiple carboxylase deficiency (2), propionic aciduria (3)
Fatty acid beta oxidation MTP (2), MCAD (2), VLCAD (1), unspecified (1)
Urea cycle CPS1 (3), OCT (1)
Other Galactosemia (4), Unspecified intermediate metabolism (2)
Neurodegenerative, specified Ataxia teleangiectasia (1), Cockayne syndrome (2), megaloencephalic leukoencephalopathy with subcortical cysts 
(1), microphthalmia brain atrophy disease [22] (3), pontocerebellar hypoplasia-infantile spinal muscular atrophy 
[23] (1), Schinzel Gideon syndrome (2)
Neurodegenerative, unspecified Mainly affecting: basal ganglia (1), cerebellum (8), cerebellum and basal ganglia (1), cerebellum and brain stem (1), 
cerebral cortex (3), cerebral white matter (3)
Infectious HIV encephalopathy (2)
CPS: carbamyl phosphate synthetase; HIV: human immune deficiency virus; MCAD: medium-chain acyl CoA dehydrogenase; MLD: metachromatic 
leukodystrophy; MPS: mucoplysaccharidosis; MTP: mitochondrial trifunctional protein; NCL: neuronal ceroid lipofuscinosis; NPC: Niemann Pick 
disease type C; OCT: ornithine transcarbamylase; VLCAD: very-long-chain acyl CoA dehydrogenase
aThe clinical course in this disease is uncertain
bEnzymatic diagnosis unknown
Table 4: Age at the onset of symptoms of disease in children with progressive encephalopathy
0–4 weeks 1–12 months 1–5 years 6–12 years Total
n%n%n%n%n%
Metabolic 25 45.5 12 21.8 15 27.2 3 5.5 55 100
Neurodeg
enerative
2 7 . 41 9 7 0 . 451 8 . 51 3 . 72 71 0 0
Infectiousa 0 0.0 2 100 0 0.0 0 0.0 2 100
T o t a l 2 73 2 . 13 33 9 . 32 02 3 . 8 4 4 . 8 8 41 0 0
aHIV encephalopathyBMC Pediatrics 2007, 7:25 http://www.biomedcentral.com/1471-2431/7/25
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bolic diseases or metabolic deficiencies with an unusual
presentation. For example, one patient initially classified
as having an unspecified neurodegenerative disorder with
cerebellar atrophy was eventually diagnosed with juvenile
Sandhoff disease [32] at the age of 15 years. The cerebel-
lum and the basal ganglia are frequently targeted by met-
abolic deficiency or other genetically determined
disorders. The majority of our unspecified neurodegener-
ative cases demonstrated neural loss in these particular
areas.
The clinical course in the neurodegenerative group, both
known and unspecified, appeared generally less aggressive
than for those in the metabolic group. The proportion
with neonatal onset was significantly less compared to the
metabolic group. Also, the median age of diagnosis was
considerably increasesed in the neurodegenerative com-
pared to the metabolic group. On the other hand, the
prospect of therapeutic measures is almost non-existent
relative to the increasing number of metabolic diseases
which have become amenable to treatment, such as lyso-
somal storage disorders [33].
Conclusion
The incidence rate of PE in children was estimated to be
between 6.0 and 6.5 per 100,000 person years, while the
cumulative incidence was 0.6 per 1000 live births. Almost
two-thirds of the cases were metabolic disorders, and one-
third other neurodegenerative diseases. Unspecified neu-
rodegenerative diseases accounted for one-fifth of all
cases. There was a strong reduction in the risk of PE with
increasing age. This trend was most noticeable in the met-
abolic group, in which less than half had neonatal presen-
tation. The neurodegenerative group was characterized by
a later onset of symptoms and a markedly older age at the
time of diagnosis.
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